Toi M - Search Results

1

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP. Johnston S, et al. Among authors: toi m. NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 30675515 Free PMC article.

2

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.

Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group. Iwata H, et al. Among authors: toi m. Breast Cancer. 2005;12(2):99-103. doi: 10.2325/jbcs.12.99. Breast Cancer. 2005. PMID: 15858439 Free article. Clinical Trial.

3

A pilot phase II study of capecitabine in advanced or recurrent breast cancer.

Saeki T, Kimura T, Toi M, Taguchi T. Saeki T, et al. Among authors: toi m. Breast Cancer. 2006;13(1):49-57. doi: 10.2325/jbcs.13.49. Breast Cancer. 2006. PMID: 16518062 Free article. Clinical Trial.

4

Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.

Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG). Toi M, et al. Breast Cancer Res Treat. 2008 Aug;110(3):531-9. doi: 10.1007/s10549-007-9744-z. Epub 2007 Sep 19. Breast Cancer Res Treat. 2008. PMID: 17879158 Clinical Trial.

5

Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.

Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Saji S, et al. Among authors: toi m. Oncology. 2007;72(5-6):330-7. doi: 10.1159/000113062. Epub 2008 Jan 12. Oncology. 2007. PMID: 18187954 Clinical Trial.

6

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.

Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S. Tokudome N, et al. Among authors: toi m. Anticancer Drugs. 2008 Aug;19(7):753-9. doi: 10.1097/CAD.0b013e328302eb15. Anticancer Drugs. 2008. PMID: 18594220 Clinical Trial.

7

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K, Suzuki E. Nakamura S, et al. Among authors: toi m. Breast Cancer. 2010 Jul;17(3):199-204. doi: 10.1007/s12282-009-0139-3. Epub 2009 Aug 1. Breast Cancer. 2010. PMID: 19649686

8

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Toi M, et al. Br J Cancer. 2009 Nov 17;101(10):1676-82. doi: 10.1038/sj.bjc.6605343. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844234 Free PMC article. Clinical Trial.

9

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.

Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M. Toi M, et al. BMC Cancer. 2010 Feb 23;10:56. doi: 10.1186/1471-2407-10-56. BMC Cancer. 2010. PMID: 20178580 Free PMC article.

10

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.

Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Toi M, et al. Cancer. 2010 Jul 1;116(13):3112-8. doi: 10.1002/cncr.25206. Cancer. 2010. PMID: 20564629 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

769 results

Search Page